DEFA14A: STAAR Surgical Details Alcon Merger Employee Terms

STAAR Surgical's CEO provided employees with an update on the Alcon acquisition, detailing compensation, benefits, and equity award treatment post-merger.

Summary

• STAAR Surgical Company has entered into a definitive agreement to be acquired by Alcon.
• The transaction is subject to closing conditions, including adoption by a majority of STAAR stockholders and antitrust approvals in several countries.
• A preliminary merger proxy statement has been filed with the U.S. Securities and Exchange Commission (SEC), and submissions to antitrust regulators have commenced.
• Until the merger closes, STAAR and Alcon will operate as separate companies, with employee compensation and benefits continuing as usual.
• For one year after closing, Alcon has agreed to provide continuing STAAR employees with no reduction in base salary, bonus opportunities no less favorable than Alcon's, and substantially comparable aggregate employee benefits.
• A new broad-based severance plan is expected to be adopted, offering cash severance equal to two weeks of base pay per year of service, with a minimum of 12 weeks (26 weeks for directors or above) and a maximum of 52 weeks for involuntary terminations without cause during the first year post-merger.
• Existing employment, severance, and change in control agreements will survive the merger and continue to apply.
• Shares of STAAR common stock will convert into the right to receive $28 per share in cash upon closing.
• In-the-money stock options (exercise price less than $28) will vest and convert to a cash payment equal to the difference between $28 and the exercise price.
• Out-of-the-money stock options (exercise price $28 or more) will be cancelled without payment.
• Restricted Stock Units (RSUs) granted before August 4, 2025, will vest and convert to $28 cash per share; those granted on or after August 4, 2025, will generally convert into Alcon RSUs.
• Performance Stock Units (PSUs) will vest and convert to $28 cash per share, with performance deemed achieved at 160% of target.
• Trading in STAAR common stock is permitted according to the company's Insider Trading Policy, subject to blackout periods and pre-clearance, and prohibition against trading while in possession of material non-public information (MNPI).

Sentiment

Score: 7

Explanation: The sentiment is generally positive, as the filing provides clarity and favorable terms for employees regarding compensation, benefits, and equity treatment post-merger. Shareholders are confirmed to receive a cash payout. However, potential job eliminations and the cancellation of out-of-the-money options introduce minor negative aspects.

Positives

• Employees will receive no reduction in base salary or wages for one year post-merger.
• Bonus opportunities will be no less favorable than those provided by Alcon to similarly situated employees.
• Employee benefits will be substantially comparable in the aggregate to Alcon's for one year.
• A broad-based severance plan will be implemented, providing clear benefits for involuntary terminations.
• In-the-money stock options, RSUs (pre-August 4, 2025), and PSUs will vest and convert to cash at $28 per share, with PSUs achieving 160% of target.
• The acquisition is expected to create exciting career opportunities for STAAR team members and make EVO ICLs more available globally.

Negatives

• Out-of-the-money stock options (exercise price $28 or more) will be cancelled without payment.
• There is a possibility of job eliminations or involuntary terminations as part of integration planning, although severance benefits are provided.
• RSUs granted on or after August 4, 2025, will convert to Alcon RSUs, not cash, introducing a new equity instrument.

Risks

• The merger agreement could be terminated, or the anticipated timetable for completion could be extended.
• Failure to obtain approval of the proposed transaction from STAAR's stockholders.
• Failure to obtain required regulatory approvals or satisfy other closing conditions within expected timeframes or at all.
• Disruption of management's attention from ongoing business operations due to the proposed transaction.
• The announcement of the proposed transaction could affect STAAR's ability to retain and hire key personnel and maintain relationships with customers, suppliers, and others.
• STAAR may fail to meet expectations regarding the timing and completion of the transaction.
• The outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction.
• STAAR's stock price may decline significantly if the proposed transaction is not consummated.

Future Outlook

The company anticipates the merger will close following stockholder adoption of the merger agreement and receipt of antitrust approvals. Integration planning efforts with Alcon are underway to develop the go-forward organizational structure. Future updates will be provided as progress is made toward closing the transaction.

Management Comments

• "We're confident this transaction serves the best interest of STAAR team members, patients, customers, and shareholders."
• "Until the transaction closes, both STAAR and Alcon must continue to operate as separate companies with business as usual."
• "We continue to believe that joining forces with Alcon will create exciting career opportunities for STAAR team members and will make EVO ICLs more available to patients and surgeons worldwide."
• "This acquisition marks a new chapter of opportunity for STAAR, and the company is excited to embark on this journey."

Industry Context

The acquisition by Alcon, a global leader in eye care, is expected to enhance the availability of STAAR's EVO ICLs to a broader patient and surgeon base worldwide, aligning with the trend of consolidation and expansion in the ophthalmology sector to leverage larger distribution networks and R&D capabilities.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• There is a risk of legal proceedings being instituted against STAAR related to the proposed transaction, as mentioned in the forward-looking statements.

Stakeholder Impact

• **Shareholders:** Will receive $28 per share in cash for their common stock, and cash for in-the-money equity awards, providing a clear exit value.
• **Employees:** Will maintain base salary, receive comparable benefits and bonus opportunities for one year, and be covered by a new severance plan. Some may face job changes or eliminations, while others will have new career opportunities within Alcon.
• **Patients and Surgeons:** The merger is expected to increase the availability of EVO ICLs worldwide, potentially benefiting patient access to the technology.
• **Customers and Suppliers:** The announcement could disrupt existing relationships, though management aims to minimize this.

Next Steps

• STAAR stockholders will hold a special meeting to vote on the adoption of the merger agreement.
• Antitrust regulators in several countries will review the transaction for approval.
• STAAR and Alcon will continue integration planning efforts to determine the go-forward organizational structure.
• STAAR expects to adopt a new broad-based severance plan before the closing of the merger.
• The Compensation Committee will determine the 2025 corporate bonus plan achievement and funding.

Key Dates

Recommendation

The filing confirms the terms of the previously announced acquisition, including the $28 per share cash consideration for STAAR common stock. For investors, the primary decision point (the merger) has been publicly known. Holding shares until the closing allows for the realization of the cash consideration, assuming the merger proceeds as expected and no significant adverse events occur that would jeopardize the transaction. There is no new operational or financial performance data in this filing to warrant a change in the fundamental investment thesis beyond the merger terms.

Keywords

STAAR Surgical, Alcon, Merger, Acquisition, Employee Compensation, Benefits, Equity Awards, Proxy Statement, Corporate Governance, Ophthalmology, EVO ICL